Welcome to our dedicated page for Inspira Technologies Oxy Bhn SEC filings (Ticker: IINN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inspira Technologies Oxy B.H.N. Ltd. filings document foreign-private-issuer current reports, shareholder meeting materials and registration statement incorporation for its technology business. Form 6-K reports furnish press releases on AME system orders, commercial deployments, the QTREX platform, cryogenic interconnect development and shareholder communications, while proxy materials cover voting matters such as amendments to the company's articles of association.
Other filings describe governance and officer appointments, ordinary-share voting procedures, Form F-3 and Form S-8 registration statement references, and capital-structure context tied to the company's Nasdaq-listed securities and medical technology operations.
Inspira Technologies Oxy B.H.N. Ltd. secured a $596,000 purchase order for an Additively Manufactured Electronics (AME) system from a leading Irish technological research university. The order includes a non-refundable 40% upfront payment, already received, with the remainder due on delivery.
The AME installation is expected to generate recurring revenue from proprietary consumables, wear parts, and annual service fees over the system’s lifetime. Inspira plans to deliver and deploy the system in the coming weeks, using this site as a potential reference installation for further academic and commercial engagements in Europe and beyond.
Inspira Technologies OXY B.H.N. Ltd. entered a Joint Development Agreement with Qarakal Quantum, a superconducting quantum computing company, to develop and test cryogenic interconnect solutions for quantum systems. The collaboration uses Inspira’s QTREX Additively Manufactured Electronics platform inside Qarakal’s superconducting quantum environment.
The agreement sets a structured, multi-phase engineering program in which Qarakal defines technical requirements and success metrics, while Inspira supplies 3D‑printed conductive and insulating structures for evaluation at milli‑Kelvin temperatures. This initiative marks a strategic expansion of Inspira’s quantum connectivity business alongside its existing respiratory support and blood monitoring medical technology portfolio.
Inspira Technologies Oxy B.H.N. Ltd. reported a fully paid $390,000 purchase order for its additive manufacturing electronics (AME) system from a premier Asia-Pacific technological research university focused on quantum computing.
The order was prepaid before shipment and is structured to generate ongoing recurring revenue from consumables and annual service fees. Inspira plans to deliver and deploy the AME system in the coming weeks, along with advanced application training for the university’s quantum research teams.
Inspira Technologies OXY B.H.N. Ltd filed an initial Form 3 for Chief Business Officer Yoav Rozanovich. This statement of beneficial ownership, based on the provided data, shows no reported common stock or derivative holdings and records no buy, sell, gift, or option exercise activity.
Inspira Technologies OXY B.H.N. Ltd. reports the successful commercial delivery and acceptance of its Additively Manufactured Electronics (AME) system at a Tier-1 U.S. defense customer site under a commercial agreement. The customer operates in advanced areas such as quantum computing, quantum networking, integrated photonics, and superconducting systems, where complex integration and extreme miniaturization are critical.
The engagement includes ongoing supply of proprietary consumables and materials, creating a contractual basis for recurring revenue beyond the initial system sale, with added potential from application-specific adaptations as usage grows. Management describes this deployment as tangible commercial execution of Inspira’s AME strategy in a top-tier defense environment and views it as evidence of commercial demand for the platform. Inspira is focused on quantum connectivity hardware while continuing to advance its medical technology portfolio.
Inspira Technologies Oxy B.H.N. Ltd. has called an Extraordinary General Meeting of shareholders for May 6, 2026, at 12:00 p.m. Israel time in Ra’anana. Shareholders of record at the close of business on April 21, 2026 are entitled to receive notice and vote.
The single proposal asks shareholders to approve changing the company’s name to “QTREX Ltd.”, or a similar name approved by the Israeli Registrar of Companies, and to amend the articles of association accordingly. Approval requires a Simple Majority of votes cast, and the Board unanimously recommends voting in favor.
The materials detail quorum rules, proxy voting for shareholders of record and beneficial owners, and procedures for submitting additional agenda items and position statements under Israeli law. The 6-K also incorporates these meeting materials by reference into several existing Form F-3 and Form S-8 registration statements.
Inspira Technologies Oxy B.H.N. Ltd. filed a report announcing the appointment of Mr. Yoav Rozanovich, age 37, as Chief Business Officer. He previously served as VP Global Customer Success at Nano Dimension Ltd. from February 2021 to April 2026, and as Global Application Engineering Director at Nano Dimension Technologies Ltd. from 2019 to 2021. Inspira plans to enter into its standard indemnification agreement with him on terms similar to those for its other directors and executive officers. This report, including its exhibit, is incorporated by reference into Inspira’s existing registration statements on Form F-3 and Form S-8.
Inspira Technologies OXY B.H.N. Ltd. filed a Form 6-K announcing the appointment of Yoav Rozanovich as Chief Business Officer. The company highlights his international commercial experience in additive manufacturing, advanced electronics, and complex systems integration, including senior roles at Nano Dimension, Stratasys, and Orbotech.
As CBO, he will lead Inspira’s commercial strategy with a focus on near-term revenue execution and scalable, long-term market expansion, particularly around its revenue-generating Additive Manufacturing of Electronics business and new quantum computing connectivity offerings. Inspira continues to develop quantum connectivity solutions for dilution cryostats alongside a dedicated medical technology business unit.
Inspira Technologies OXY B.H.N. Ltd. has begun implementing its AME (Additive Manufactured Electronics) technology with a customer described as one of the world's 10 largest U.S.-based companies. The rollout is underway at a U.S. research and development facility integrated into an advanced corporate technology infrastructure.
The engagement focuses on using Inspira’s AME platform for cryogenic connectivity in quantum computing, addressing critical scaling bottlenecks. Inspira views this as validation of its AME technology, reinforcing a recurring revenue relationship and signaling broader demand from elite technology organizations, while it continues to develop its medical technology portfolio.
Inspira Technologies OXY B.H.N. Ltd. is pivoting into the quantum computing sector, redirecting its recently acquired additive manufactured electronics (AME) platform to solve connectivity bottlenecks inside dilution cryostats. The AME technology, developed with over $200 million of investment, has already shown proof of concept in qubit device integration.
The shift is led by CEO Dagi Ben‑Noon and COO Avi Shabtay, who originally developed the AME technology and previously worked at Nano Dimension, alongside other former Nano Dimension personnel. Inspira plans to keep advancing its INSPIRA ART100 respiratory system and HYLA blood monitoring system under a dedicated medical unit.
The company intends to seek shareholder approval to change its name to QTREX Ltd. and has launched a QTREX website to reflect its focus on quantum connectivity solutions, while continuing commercial discussions in both quantum and medical markets.
Inspira Technologies OXY B.H.N. Ltd. is pivoting into the quantum computing sector, redirecting its recently acquired additive manufactured electronics (AME) platform to solve connectivity bottlenecks inside dilution cryostats. The AME technology, developed with over $200 million of investment, has already shown proof of concept in qubit device integration.
The shift is led by CEO Dagi Ben‑Noon and COO Avi Shabtay, who originally developed the AME technology and previously worked at Nano Dimension, alongside other former Nano Dimension personnel. Inspira plans to keep advancing its INSPIRA ART100 respiratory system and HYLA blood monitoring system under a dedicated medical unit.
The company intends to seek shareholder approval to change its name to QTREX Ltd. and has launched a QTREX website to reflect its focus on quantum connectivity solutions, while continuing commercial discussions in both quantum and medical markets.